Krystal Biotech Past Earnings Performance
Past criteria checks 2/6
Krystal Biotech's earnings have been declining at an average annual rate of -33.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 107.6% per year. Krystal Biotech's return on equity is 1.4%, and it has net margins of 21.6%.
Key information
-33.7%
Earnings growth rate
-24.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 107.6% |
| Return on equity | 1.4% |
| Net Margin | 21.6% |
| Next Earnings Update | 06 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Krystal Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 51 | 11 | 98 | 46 |
| 30 Sep 23 | 9 | -30 | 98 | 46 |
| 30 Jun 23 | 0 | -140 | 94 | 47 |
| 31 Mar 23 | 0 | -135 | 86 | 45 |
| 31 Dec 22 | 0 | -140 | 79 | 42 |
| 30 Sep 22 | 0 | -130 | 69 | 41 |
| 30 Jun 22 | 0 | -115 | 59 | 35 |
| 31 Mar 22 | 0 | -104 | 51 | 31 |
| 31 Dec 21 | 0 | -70 | 42 | 28 |
| 30 Sep 21 | 0 | -58 | 32 | 25 |
| 30 Jun 21 | 0 | -52 | 27 | 24 |
| 31 Mar 21 | 0 | -43 | 21 | 21 |
| 31 Dec 20 | 0 | -32 | 15 | 18 |
| 30 Sep 20 | 0 | -27 | 12 | 17 |
| 30 Jun 20 | 0 | -22 | 9 | 15 |
| 31 Mar 20 | 0 | -20 | 7 | 16 |
| 31 Dec 19 | 0 | -19 | 6 | 16 |
| 30 Sep 19 | 0 | -17 | 6 | 14 |
| 30 Jun 19 | 0 | -16 | 6 | 12 |
| 31 Mar 19 | 0 | -13 | 5 | 9 |
| 31 Dec 18 | 0 | -11 | 4 | 8 |
| 30 Sep 18 | 0 | -9 | 3 | 6 |
| 30 Jun 18 | 0 | -11 | 3 | 5 |
| 31 Mar 18 | 0 | -10 | 2 | 4 |
| 31 Dec 17 | 0 | -8 | 2 | 3 |
| 30 Sep 17 | 0 | -7 | 1 | 3 |
| 30 Jun 17 | 0 | -2 | 1 | 1 |
Quality Earnings: 4KB has a high level of non-cash earnings.
Growing Profit Margin: 4KB became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4KB has become profitable over the past 5 years, growing earnings by -33.7% per year.
Accelerating Growth: 4KB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4KB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 4KB's Return on Equity (1.4%) is considered low.